Cupid shares rose 6% to Rs 210.90 apiece on the NSE on Monday, extending the week’s rally to over 11%. The company’s stock has been rising since its June 2026 quarterly business report.
The company is on track to post revenue in excess of Rs 150 crore in the first quarter of FY27, which would be one of the strongest quarterly performances in its history, according to exchange data.
Cupid said that with this exceptional start to the fiscal year and improved visibility in international and domestic markets, management has revised FY27 earnings guidance upward by at least 10%. This means the company expects FY27 revenue to be over Rs 660 crore, up from the previous forecast of Rs 600 crore.
Also read | Diamond Power Infrastructure shares jump 10% following Rs 435 crore order for data center projects in Hyderabad
The revised outlook reflects growing confidence in the company’s diversified business model, expansion of its global portfolio of capabilities and increased scale of operations across multiple business verticals. 
Live Events
According to the company, growth is expected to be supported by expanding opportunities in international B2B healthcare markets driven by demand from institutional buyers, private sector clients and government procurement programs.
This outlook is also supported by the commencement of a long-term supply agreement with Partnership for Supply Chain Management (PFSCM), the Netherlands, which the company says strengthens its position in global healthcare procurement. The company also highlighted growing opportunities in its lubricants portfolio driven by growing acceptance through institutional and consumer channels. The company said its consumer business offers significant long-term potential as it continues to expand its personal care and health brand through modern trade, organized retail and pharmacy chains across Bharat.
Cupid said it sees high order visibility from private markets, institutional business and international tenders spanning multiple geographies. The Company expects continued growth in its male and female condom business, driven by the expansion of production capacity, new customer acquisitions and market penetration achieved over the past 12 months.
The company also said it is making steady progress in its in vitro diagnostics (IVD) business. While near-term growth expectations remain conservative, the company expects the segment to contribute meaningfully in the coming years, driven by regulatory approvals, new product launches and ongoing commercialization efforts.
“Our strong start to FY27 reflects the transformation Cupid has undergone over the past few years. We have built a diversified business with multiple growth engines that are now starting to scale together,” said Aditya Kumar Halwasiya, Chairman and Managing Director, Cupid.
Also read | Vedanta and TCS were among the top five stocks with the highest dividend yield. Check details
Halvasiya further said, “We see strong momentum in our international B2B business, driven by expanding opportunities in private markets, institutional procurement and government tenders around the world. Our strategic relationship with PFSCM has started on a very encouraging note and further strengthens our long-term position in global healthcare procurement.”
He added that backed by a strong order book, improved visibility in international markets and a broad range of opportunities, the company has revised its medium-term revenue forecast upward. “At the same time, we believe our guidance remains conservative, leaving room for additional upside as execution continues and new opportunities are realized,” he said.
Cupid shares are up 16.14% over the past two weeks and more than 52% over the past month.
(Disclaimer: Recommendations, suggestions, views and opinions expressed by experts are their own. They do not reflect the views of The Economic Times.)